Get the Stockscreener App
4.10
2.50%
0.10
Intensity Therapeutics Inc stock is traded at $4.10, with a volume of 4,451.
It is up +2.50% in the last 24 hours and down -1.91% over the past month.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
See More
Previous Close:
$4.00
Open:
$3.99
24h Volume:
4,451
Relative Volume:
0.11
Market Cap:
$13.39M
Revenue:
-
Net Income/Loss:
$-10.69M
P/E Ratio:
-0.5789
EPS:
-7.0818
Net Cash Flow:
$-9.07M
1W Performance:
-3.53%
1M Performance:
-1.91%
6M Performance:
-46.75%
1Y Performance:
-40.26%
1-Day Range:
$3.99
$4.11
1-Week Range:
$3.99
$4.28
52-Week Range:
$3.51
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
4.10 | 15.93M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity (INTS) Results Review: EPS Comes in Above Forecast in the Current Update - vinanet.vn
H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
H.C. Wainwright reiterates Buy on Intensity Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Intensity Therapeutics stock - Investing.com
INTS Stock Price, Quote & Chart - ChartMill
INTENSITY THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $7 FROM $5 - Bitget
INTS Maintained by HC Wainwright & Co. -- Price Target Raised to $7.00 - GuruFocus
H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Intensity Therapeutics (INTS) Dips 1% to $3.96, Trading Range Holds with Support at $3.76Zero Lag EMA - Vinanet
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com UK
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Intensity Therapeutics Warns of Substantial Doubt - Minichart
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade
INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView
Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView
Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus
Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView
Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView
INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView
BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView
INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView
BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView
Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Stock News Today - TradingKey
INTS Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Rise 1.64%Management Tone Analysis - vinanet.vn
Intensity Therapeutics (INTS.US) will release its earnings report before the market opens on August 11. - Moomoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
INTS Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
INTS|Intensity Therapeutics Inc|Price:3.960|Chg%:-0.040 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesFinancial Data - vinanet.vn
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):